Neuromodulation company Nevro has raised $58 million in venture capital funding. The investment was led by new investor Johnson & Johnson Development Corporation. Existing investors, including Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital and Three Arch Partners, also participated. The company intends to use the proceeds to fund a pivotal clinical study in the U.S. and offer support for its international commercialization strategy.

Click here for the release from Business Wire.